Literature DB >> 8150540

Association of IgA-anti-Fab autoantibodies with disease stage in head-and-neck cancer.

C Süsal1, H Maier, K Lorenz, G Opelz.   

Abstract

Patients with head-and-neck cancer commonly have immune defects. It was reported that these patients have raised serum IgA levels. We investigated whether IgA-anti-Fab autoantibodies, which occur in association with immune dysfunction, are present in patients with head-and-neck cancer. Sera of 101 patients with squamous-cell carcinoma (SCCHN) and 8 patients with adenoid cystic carcinoma (ACCHN) of the head and neck were tested in ELISA for IgA-anti-Fab autoantibody activity. IgA-anti-Fab serum activity was significantly higher in both SCCHN and ACCHN patients than in healthy controls. In patients with SCCHN, an association between disease stage and IgA-anti-Fab activity was established. Stage-IV patients had significantly higher IgA-anti-Fab than stage-I patients or healthy controls. Stage-II and stage-III patients had intermediate levels. Extremely high IgA-anti-Fab activity was observed in 7 patients who died within 6 months following testing, suggesting a relationship of autoimmunity with terminal disintegration of physiological body functions. IgA-anti-Fab autoantibodies may explain the occurrence of immune defects in patients with head-and-neck cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8150540     DOI: 10.1002/ijc.2910570109

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.

Authors:  Randall J Brezski; Michelle Kinder; Katharine D Grugan; Keri L Soring; Jill Carton; Allison R Greenplate; Theodore Petley; Dorie Capaldi; Kerry Brosnan; Eva Emmell; Sharon Watson; Robert E Jordan
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

2.  Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1.

Authors:  M C Holland; J U Wurthner; P J Morley; M A Birchler; J Lambert; M Albayaty; A P Serone; R Wilson; Y Chen; R M Forrest; J C Cordy; D A Lipson; A I Bayliffe
Journal:  J Clin Immunol       Date:  2013-07-06       Impact factor: 8.317

3.  Pre-existing canine anti-IgG antibodies: implications for immunotherapy, immunogenicity testing and immunoassay analysis.

Authors:  Daniel Bergman; Camilla Bäckström; Helene Hansson-Hamlin; Anders Larsson; Bodil Ström Holst
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

4.  IgG anti-hinge antibodies against IgG4 F(ab')2 fragments generated using pepsin are useful diagnostic markers for rheumatoid arthritis: implications of the possible roles of metalloproteinases and IgG subclasses in generating immunogenic hinge epitopes.

Authors:  Toshiyuki Ota; Shun-Ichiro Ota; Ayumi Uchino; Shuji Nagano
Journal:  Arthritis Res Ther       Date:  2020-06-26       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.